<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2297">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04736901</url>
  </required_header>
  <id_info>
    <org_study_id>COVID-Anticoagulants</org_study_id>
    <nct_id>NCT04736901</nct_id>
  </id_info>
  <brief_title>Effect of Prophylactic and Therapeutic Anticoagulants in Egyptian Patients With COVID-19</brief_title>
  <official_title>Effect of Prophylactic and Therapeutic Anticoagulants in Egyptian Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Misr International University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since the end of 2019, Egypt and the whole world have been suffering from the Coronavirus&#xD;
      Disease 2019 (COVID-19) pandemic, which is caused by the severe acute respiratory syndrome&#xD;
      coronavirus 2 (SARS-CoV-2). According to the World Health Organization (WHO), since the&#xD;
      emergence of this new pandemic, there have been more than 97 million confirmed cases of&#xD;
      COVID-19 patients and two million death globally; around 160 thousand of these cases are in&#xD;
      Egypt.&#xD;
&#xD;
      Recent clinical investigations found a high incidence of thrombotic complications in these&#xD;
      patients, even with the standard anticoagulant thromboprophylaxis.Coronavirus disease 2019&#xD;
      (COVID-19) causes a hypercoagulable state. Among the pathological sequel of COVID-19&#xD;
      infection, is the presence of a micro-thrombi in the pulmonary circulation which was shown in&#xD;
      several autopsy studies. This thrombosis is believed to contribute to gas exchange impairment&#xD;
      among patients with COVID-19 infection.&#xD;
&#xD;
      Some observational studies have shown anticoagulation benefits with reduced mortality, mainly&#xD;
      in patients requiring mechanical ventilation. However, these findings remain uncertain and&#xD;
      need to be validated in further studies.&#xD;
&#xD;
      This study is performed to evaluate whether therapeutic anticoagulation could improve&#xD;
      COVID-19 patients' clinical outcomes compared to prophylactic anticoagulation in terms of&#xD;
      improving gas exchange, reducing the need to maintain mechanical ventilation, shortening&#xD;
      hospital admission period and mortality rate as well as recovering D-dimmer levels to its&#xD;
      normal values.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in clotting factors level</measure>
    <time_frame>Two weeks</time_frame>
    <description>Difference in clotting factors levels between baseline during inclusion in the study and before discharge.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in gas exchange over time</measure>
    <time_frame>Two weeks</time_frame>
    <description>Difference between ratio of partial pressure of arterial oxygen (PaO2) to the fraction of inspired oxygen (FiO2) at baseline, and before discharge.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to increase in oxygenation</measure>
    <time_frame>Two weeks</time_frame>
    <description>Time to increase in SpO2/FiO2 of 50 or greater compared to the baseline SpO2/FiO2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>Two weeks</time_frame>
    <description>Length of hospital stay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Monitoring of adverse events</measure>
    <time_frame>Two weeks</time_frame>
    <description>Any signs or symptoms of bleeding will be monitored daily</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In hospital mortality rate</measure>
    <time_frame>Two weeks</time_frame>
    <description>Death occurrence during hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monitoring of hemoglobin levels.</measure>
    <time_frame>Two weeks</time_frame>
    <description>Difference in hemoglobin levels between baseline during inclusion in the study and before discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monitoring of platelets levels</measure>
    <time_frame>Two weeks</time_frame>
    <description>Difference in platelets levels between baseline during inclusion in the study and before discharge</description>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Covid19</condition>
  <condition>Corona Virus Infection</condition>
  <condition>Hypercoagulability</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Enoxaparin therapeutic dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Enoxaparin prophylactic dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>Rivaroxaban therapeutic dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <description>Rivaroxaban prophylactic dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <description>Apixaban therapeutic dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <description>Apixaban prophylactic dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>0.5 mg/kg every 12 hours</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>40 mg/day</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>10 mg once daily</description>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>20 mg once daily</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>2.5 mg twice daily</description>
    <arm_group_label>Group 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>5 mg twice daily</description>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The current research is including moderate and severe SARS-COV-2 patients receiving the&#xD;
        same background treatment for 5 days, following an Institutional protocol for standard of&#xD;
        care: hydroxychloroquine 400 mg daily, lopinavir/ritonavir 400/100 mg twice daily or/and&#xD;
        remdisivir 200 mg LD then 100 once daily as a maintenance dose and anti-coagulation&#xD;
        prophylaxis with enoxaparin subcutaneously once a day if D-dimmer between 500-1000 or&#xD;
        enoxaparin therapeutic subcutaneously twice daily if D-dimmer &gt;1000.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 to 65 years..&#xD;
&#xD;
          2. COVID-19 hospitalized patients with pneumonia proved by chest X-ray or CT scan.&#xD;
&#xD;
          3. Confirmed infection with COVID-19 virus using RT-PCR or strongly suspected to be&#xD;
             infected with pending confirmation studies.&#xD;
&#xD;
          4. Prothrombin time/international normalized ratio (INR)&lt;1.5; activated partial&#xD;
             thromboplastin time (aPTT)/ratio&lt;1.5, and platelet count greater than 100,000/mm3.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age greater than 85 years-old&#xD;
&#xD;
          2. Creatinine clearance (CrCl)&lt;10ml/min.&#xD;
&#xD;
          3. Severe circulatory shock with a dose of norepinephrine higher than 1.0 Î¼g/kg/min.&#xD;
&#xD;
          4. Pregnant women.&#xD;
&#xD;
          5. Recent major surgery or severe trauma in the last 3 weeks or recent hemorrhagic stroke&#xD;
             in the last 3 months.&#xD;
&#xD;
          6. Active bleeding, blood dyscrasia such as hemophilia and Von Willebrand factor&#xD;
             deficiency.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Neven Sarhan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Misr International University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Neven Sarhan, PhD</last_name>
    <phone>01021944422</phone>
    <email>sarhanneven@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>mona farag schaalan, PhD</last_name>
    <email>mona.schaalan@miuegypt.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Teachers Hospital</name>
      <address>
        <city>Cairo</city>
        <state>Please Select</state>
        <zip>11314</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neven Sarhan, PhD</last_name>
      <phone>01021944422</phone>
      <email>sarhanneven@gmail.com</email>
    </contact>
    <contact_backup>
      <phone_ext>schaalan</phone_ext>
      <email>mona.schaalan@miuegypt.edu.eg</email>
    </contact_backup>
    <investigator>
      <last_name>Neven M. Sarhan, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mona F schaalan, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shaimaa Fathy, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmed Essam, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 1, 2021</study_first_submitted>
  <study_first_submitted_qc>February 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 3, 2021</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Misr International University</investigator_affiliation>
    <investigator_full_name>Neven Sarhan</investigator_full_name>
    <investigator_title>Lecturer at Faculty of Pharmacy</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Hypercoagulability</keyword>
  <keyword>Anticoagulants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Thrombophilia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

